Drug Type Single-chain FV antibody fragment |
Synonyms 4B5 scFv antibody (Novopharm), anti-GD2 antibody (Viventia) |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Melanoma, Cutaneous Malignant | Phase 2 | - | 01 Aug 1998 |






